cyrilzakka/clinical-trials huggingface dataset:
Effect of Quadratus Lumborum Muscle Energy Technique in Sacroilliac Joint Dysfunction.

Sacroiliac joint as a potential source of low back pain is an overlooked problem. Yet, in the existing years there has been an increasing interest in sacroiliac joint as a pain originator and more attention is being paid into its assessment and treatment in the current literature. Muscle imbalance due to postural dysfunction involves mainly gluteus medius and hamstring; however the role of quadratus lumborum working on compensatory mechanism and its treatment effect in the management of sacroiliac joint dysfunction is yet not discovered.

Going through current literature, it is evident that sacroiliac joint dysfunction as a postural dysfunction is highly prevalent among adult population. This dysfunction due to major muscle imbalances if not treated timely can result in serious consequences later in life where it becomes the permanent dysfunction involving the major changes in the joint itself. Muscle imbalance due to postural dysfunction involves mainly gluteus medius and hamstring; however the role of quadratus lumborum working on compensatory mechanism and its treatment effect in the management of sacroiliac joint dysfunction is yet not discovered. All patients will be assessed and screened by consultants as indicated and will refer to physiotherapy with diagnosed non- specific chronic back pain.Patients will further be screened for SIJ dysfunction by physiotherapist.Only those patients who fulfill the criteria of Quadratus lumborum tightness \& Gulteus medius weakness will randomly be selected and the sample of 70 will finally be selected for intervention.Written consent form will be taken from all study participants.Simple randomization technique will be used through "Randomization Main" software and randomization sheet will be generated. Patients will be further be assigned equally into two groups as per randomization sheet.Treatment will be performed three sessions per week for 4 weeks with postural advice and home exercise program with daily record of home diary. The selected outcome measures will be taken on initial visit (pre intervention), session 6 and final session 12 (post intervention).

Eligibility Criteria:
Inclusion Criteria:

* • Subjects with unilateral non-specific LBP

  * The Subjects having at least 3 pain provocative tests of SIJ positive out of 5.
  * Age 30-50 years. Both male and female.
  * Pain history greater than six weeks.
  * SIJ diagnostic scoring cut off point 4.
  * VAS cut off point mild to moderate.

Exclusion Criteria:

* Radiating pain with sensory or motor deﬁcits.
* History of fracture or any spinal surgery
* Trauma
* Any dysfunction of hip or knee
* Any systemic disease.
* Pregnancy
High-risk Features of Coronary Lesions in CTA and OCT

This study is a multicenter and retrospective study. ACS patients who underwent CCTA or OCT from 1 months to 3 years prior to the event will be retrospectively identified. Plaques in the non-culprit vessels will be regarded as a primary control group.

The high-risk features of plaque rupture and subsequent acute coronary syndrome (ACS) are not fully identified. Plaque features, hemodynamic forces, and the interaction between these factors may cause plaque instability and subsequent clinical events. A previous study showed that the addition of hemodynamic parameters calculated noninvasively from coronary computed tomography (CCTA) using computational fluid dynamics (such as wall shear stress and axial plaque stress) improved the ability to predict the risk of ACS compared with conventional approaches based on anatomical stenosis severity and adverse plaque characteristics. Wall shear stress and axial plaque stress derived from CT were highly correlated to those derived from optical coherence tomography (OCT). In addition, other hemodynamic parameters, such as oscillatory shear index, endothelial shear stress (ESS), and spatial ESS gradient have also been demonstrated to be associated with unstable plaque. In this regard, we designed this study to find the best hemodynamic and plaque features derived from CTA and verified by OCT to predict ACS, and to investigate whether a comprehensive risk prediction model with them has an incremental value in a larger population.

Eligibility Criteria:
Inclusion Criteria:

1. Patients who presented with ACS and underwent invasive coronary angiography or OCT
2. The patients who underwent coronary CT angiography, regardless of the reason (for example, routine healthcare check-up, or evaluation for stable angina or atypical chest pain) prior to the acute event.
3. Time limit of CCTA: 1 months \~ 3 years prior to the event.

   * Exclusion Criteria:

Patients with stents in two or more vessel territories prior to CCTA Poor quality of CCTA which is unsuitable for plaque and CFD analysis Patients with ACS culprit lesion in a stented segment Patients with previous history of coronary artery bypass graft surgery Patients with revascularization after CCTA and before ACS event Secondary ACS due to other general medical conditions, such as sepsis, arrhythmia, bleeding, etc.

--Additional exclusion criteria for Computational Fluid Dynamics Poor quality CCTA images unsuitable for CFD and plaque analysis No unprocessed CCTA data
Aortic Valve Replacement With Trifecta(TM)

The purpose of this study is to confirm the clinical safety and effectiveness of the Trifecta valve.

The clinical investigation is a multi-center, multi-country, prospective, non-randomized, observational study designed to evaluate the safety and effectiveness of the Trifecta valve.

Eligibility Criteria:
Inclusion Criteria:

* Requires aortic valve replacement (heart surgery such as bypass is allowed at the same time).
* Legal age.
* Signed informed consent prior to surgery.
* Willing to complete all follow-up requirements.

Exclusion Criteria:

* Pregnant or nursing women.
* Have already had a valve replaced other than the aortic valve.
* Needs another valve replaced.
* Cannot return for required follow-up visits.
* Have active endocarditis.
* Acute preoperative neurological event (such as a stroke).
* Renal dialysis.
* History of substance abuse within one year, or a prison inmate.
* Participating in another study.
* Life expectancy less than two years.
Pilot Study of Clinician-supported Patient Self-management of Hospital Insulin Therapy

This study will examine the feasibility of implementing a clinician-supported patient self-managed inpatient insulin intervention. It will: assess the number of eligible patients presenting over time; assess patients' willingness to enroll; assess patients' ability to successfully complete the intervention; examine occurrences of hyperglycemia and hypoglycemia; and assess patients' satisfaction with inpatient diabetes care.


Eligibility Criteria:
Inclusion Criteria:

* Admitted to the Hospital of the University of Pennsylvania (HUP) in the past 72 hours.
* Current HUP locations are Founders 12, Founders 14, Silverstein 11, and Rhoads 1.
* Age 18 years or older.
* Type-1 or type-2 diabetes mellitus requiring home basal-bolus insulin therapy administered via subcutaneous injection (not pump).
* Patient manages own basal-bolus insulin therapy at home without assistance, including measuring own blood glucose (at least at mealtimes) and administering own subcutaneous insulin.
* Patient is willing to use the following insulin products: rapid-acting insulin aspart via insulin pen (NovoLog) and long-acting insulin glargine via vial and syringe (Lantus).
* Most recent hemoglobin A1c was measured within past 6 months and was \<7.5%.
* Active order for in-hospital basal-bolus or sliding-scale insulin.
* Patient is willing and able to record their self-measured blood glucose results, doses of insulin that they self-administer, a food journal, and exercise log.
* Clinical care team agrees with study inclusion.

Exclusion Criteria:

* Inpatient order for insulin via subcutaneous infusion (i.e., pump) or intravenous infusion (i.e., drip).
* Inability to perform the activities required by the trial.
* Primary reason for admission was hyperglycemia, hypoglycemia, diabetic ketoacidosis, hyperglycemic hyperosmolar nonketotic coma, a psychiatric condition, acute alcohol poisoning, or acute drug ingestion.
* Order for a newly-prescribed or increased dose of a previously-prescribed corticosteroid.
* Enteral or parenteral nutrition.
* Expected length of stay \<48h, as determined by treating physician.
* At risk for self-harm, as determined by 1-to-1 status placement.
* Pregnant, as recorded on medical record.
* Cannot understand, speak, and read English.
* Patient does not wish to utilize Novolog and Lantus while in the hospital.
* Prior enrollment in this trial.
* Do not resuscitate status.
* Inability to give written informed consent.
* Clinical care team disagrees with study inclusion.
* Patient has limited mobility such that they cannot safely access the bedside medication lockbox.
Genetic Predisposition in Cerebral Palsy

Cerebral palsy (CP) is a major neurodevelopmental disorder with an estimated prevalence of approximately one in 500 children. It is characterised by permanent developmental disorders of movement and posture, responsible for activity limitations, caused by non-progressive damage to the brain of the fetus, newborn or infant during development. The neurobiological mechanisms involved in CP remain poorly understood, although the interruption of cerebral oxygen supply during pregnancy or at the time of delivery is classically considered to be the main factor causing neurodevelopmental sequelae. CP also occurs in full-term infants without a clearly identifiable etiology.

Data from the literature suggest the existence of other pathophysiological processes than only acquired brain lesions related to pregnancy and delivery, such as genetic or epigenetic factors. According to some research teams, nearly one third of CP could have a genetic cause or could be favoured by genetic variants.

Preliminary research has made significant progress in revealing unusual copy number variants and/or mutations in single genes in children with CP. Several of the identified genes are involved in neurodevelopment and neuronal connectivity. Nevertheless, the identification of these abnormalities in CP may contribute to a better understanding of the pathophysiology of this complex and multifactorial disorder. It could also shed new light on the analysis of medico-legal files and bring encouraging perspectives by targeting new therapeutic interventions.

The main hypothesis is that a certain number of cerebral palsies are related to - or favoured by - genetic abnormalities that we will search for with genetic screening tests.


Eligibility Criteria:
Inclusion Criteria:

* Child between 2 and 15 years old with a clinical diagnostic of cerebral paralysis with unilateral or bilateral somatic involvement
* Child born from 34 SA
* Agreement of the legal representatives for the genetic study
* Both parents available for a parental genetic study (if detection of class 3 variant)
* Affiliation to the social security system

Exclusion Criteria:

* Genetic syndrome identified or malformative or infectious etiologies identified
* Neonatal encephalopathy criteria in a clear obstetrical etiological context responsible for major perinatal anoxia with Sarnat 2 or 3
* Unilateral motor disorders in perinatal stroke of identified etiology (coagulation anomaly)
Using Anonymous Data from a Digital Tool for Medical History-Taking to Improve Healthcare Services

This study aims to understand how people use a mobile app that helps them record their symptoms before going to the doctor. Patients use the app on a tablet or other digital device. The app guides patients through a series of structured questions tailored to their symptoms. The data collected is then transferred to the practice's electronic record and is available to the treating doctor before and during the consultation.

In this project, anonymized usage data will be analyzed to contribute to the further development of the tool and to provide valuable insights for health services research.

In several studies the usability of digital medical history tools has been demonstrated. These tools allow acute complaints to be recorded using an app before a medical consultation and the data collected to be transferred to the electronic medical record.

The aim of the study is to investigate the effectiveness and use of a digital medical history tool that is becoming increasingly popular in general practice. To this end, it is aimed to evaluate anonymized usage data provided by the company that distributes the app, aidminutes gUG, as part of an observational study with the aim of identifying potential for further development and for questions of health services research (e.g. on the frequency of GP consultations, morbidity and frequency of complaints). This is a retrospective data analysis of anonymous routine data in a cross-sectional design.

Eligibility Criteria:
Inclusion Criteria:

* all patients that use the app in a general practice that agreed to provide data
* all ages (including children if the app is used by parent or legal guardian)
* all complaints chosen in the app

Exclusion Criteria:

* patients that use the app in a general practice that did not agree to provide data
* patients that use the app in a general practice outside of the federal state Lower Saxony
Actions & Insights Evaluating a Novel Diabetes Management Solution

Single visit outcome study to obtain qualitative and quantitative data for a new BGMS.

During ASCEND, patients will complete a single visit clinical study divided into two distinct parts. Part 1 involves each subject completing a number of simple quantitative exercises to gauge their level of comprehension of diabetes related information. Subjects will then continue during the same visit to complete part 2 which involves gathering qualitative feedback from each subject on the new Blood glucose monitoring system.

Eligibility Criteria:
Summary off:

Inclusion Criteria:

* Diagnosed with T1DM or T2DM
* Performs SMBG
* Male or female, at least 16 years old.
* Able to communicate (speak, read and write) in English
* Willing to sign an informed consent.

Exclusion Criteria:

* Unlikely to be compliant with the study in the opinion of study staff.
* Conflict of Interest - Prospective Participants are currently working for, previously worked for, or have an immediate family member currently working for a company that manufactures or markets the products tested under this procedure
Nabilone & Marijuana Addiction

Safety of Nabilone in reducing marijuana craving

Randomized double blind trial into the safety and efficacy of Cesemat for the treatment of marijuana use

Eligibility Criteria:
Inclusion Criteria:

* 19 years or older
* History of marijuana use
Eye Movement Desensitization and Reprocessing on Autoimmune Thyroiditis in Adults

The purpose of this study is to evaluate whether Eye Movement Desensitization and Reprocessing (EMDR) is effective in decreasing the level of autoantibodies of patients with autoimmune thyroiditis. The investigators hypothesize that processing traumatic memories from events that happened before the illness onset will have a positive impact first on the psyche (a) by decreasing the level of dissociation, alexithymia, anger, and (b) by increasing the quality of life and emotional regulation, than those in the control group. Secondly, it will have an impact on the biological level, by decreasing the level of autoantibodies, antithyroglobulin antibody (anti-Tg) and anti-thyroid peroxidase antibody (anti-TPO), which are the main antibodies detected in chronic autoimmune thyroiditis.

Hashimoto thyroiditis is an autoimmune disease that leads to chronic inflammation of the thyroid gland. This is considered the most common autoimmune disorder, and the most common endocrine disorder. Psychological trauma has been suggested as a possible factor in the pathogenesis and development of autoimmune diseases. Although a diversity of psychotherapeutic interventions have been studied in adults with autoimmune diseases, there is a lack of psychological research and randomized controlled trials in the field of the Hashimoto disease.

This study is designed to be a clinical trial with three arms: one experimental and two control groups. The experimental group receives EMDR, one control group receive placebo and the other is a waiting list. 90 out-patients with Hashimoto disease will be randomly assigned to the three groups. The investigators hypothesize that the therapeutic gains will be more significant in the experimental condition than in the control groups at the completion of the therapy and that this will be maintained at the 3-month follow-up.The EMDR group undergoes a 90 minutes session of EMDR each week for twelve weeks.The sessions will be conducted by clinicians or psychotherapists specialized in EMDR. The placebo group will receive a similar amount of time of placebo intervention. If therapy is efficient on the autoimmune disorder, participants in the control groups will be reallocated to EMDR after the experimental treatment will come to an end.

Eligibility Criteria:
Inclusion Criteria:

* aged 18-55 years;
* confirmed autoimmune thyroiditis diagnosis
* at least one biological marker Anti-thyroid peroxidase (anti-TPO) antibodies or thyroglobulin antibodies (TgAb) exceeds the reference range

Exclusion Criteria:

* the presence of psychotic symptoms
* currently receiving another form of psychological treatment;
* under psychotropic medication;
* neurodevelopmental disorders (intellectual disability, communication disorders, autism spectrum disorders, ADHD);
* neurocognitive disorders;
* substance abuse;
* serious legal or health issues that would prevent from regularly attending
* patients with autoimmune thyroiditis with biological markers within the reference range
Paleo Diet 8wk Feasibility in Overweight Adults

Overweight, physically inactive but otherwise healthy adults habitually eating a traditional Western diet will follow an ad libitum self-administered Paleo diet for 8-weeks. Blood and body composition will be measured before and after the intervention period.

The Paleo diet is a dietary method that is gaining popularity among the general population due to potential weight loss and disease prevention benefits. The feasibility of the Paleo diet and the effectiveness of self-administration in improving cardiometabolic disease risk factors remains uncertain. Examination od cardiometabolic disease risk factors in overweight, physically inactive adults before and after 8-weeks of an ad libitum self-administered Paleo dietary intervention. Methods: Overweight, physically inactive but otherwise healthy adults habitually eating a traditional Western diet follow an ad libitum self-administered Paleo diet for 8-weeks. Blood samples were analyzed for fasting cardiometabolic disease biomarkers. Participants complete three-day dietary recalls prior to, and during weeks 4 and 8 of the intervention to confirm Western diet consumption at pre-, track compliance, and to assess dietary changes.

Eligibility Criteria:
Inclusion Criteria:

* Age: 18-55 years
* BMI \> 25 kg/m2
* Currently consuming a typical Western diet (high carbohydrate, low fat diet), which will be assessed using the 3-day dietary record (public domain)

Exclusion Criteria:

* known cardiovascular, metabolic (including type I or type II diabetes), or respiratory disease
* smoking and/or smokeless tobacco users
* pregnancy
Fit and Strong! Plus Comparative Effectiveness Trial

This randomized controlled trial is comparing outcomes of customary Fit and Strong!, to Fit and Strong! Plus, an enhanced version of the program that incorporates weight management. We hypothesize that Fit and Strong! Plus participants will show improved diet behaviors at 2, 6, 12, and 18 months that will be accompanied by a significant 5% weight loss at 6 months and maintained to 18 months, compared to participants in customary Fit and Strong!.


Eligibility Criteria:
Inclusion Criteria:

* Presence of symptoms of lower extremity osteoarthritis
* Age 60 or older
* Not currently participating in a regular physical activity program
* BMI 25-50
* Able to attend Fit and Strong! classes

Exclusion Criteria:

* Score of 3 or greater on Mental Status Questionnaire
* Recent hip or knee surgery
* Recent steroid injection into hip or knee
* Diagnosis of rheumatoid arthritis
* Uncontrolled diabetes
* Unspecified health conditions that may interfere with exercise
A Phase II Trial of Perifosine Following Tyrosine Kinase Inhibitor (TKI) - Failure in Patients With Renal Cancer

This is a single-arm phase II trial of perifosine in renal cancer patients who have experienced disease progression after receiving either sorafenib or sunitinib.

This is a single-arm phase II trial assessing the antitumor activity as measured by progression free survival of perifosine in patients with metastatic RCC who have progressed on sorafenib or sunitinib. A total of 48 patients will be enrolled in the trial. All subjects will have histologically confirmed metastatic RCC with predominantly clear cell features (≤ 50% other histologic features). Patients who have been taken off sorafenib or sunitinib may only have been off therapy for less than three months prior to study enrollment. Patients who remain on sorafenib or sunitinib may continue on drug at their current dose until two weeks prior to the initiation of perifosine therapy.

The study consists of three periods: pre-treatment/screening, treatment, and follow-up. Day 1 will be defined as the first day of perifosine therapy. Patients will remain in the treatment phase until progression or toxicity. Patients will be seen by an MD every 3 weeks with 6 weeks defining one cycle of therapy. Tumor evaluations will occur every 6 weeks.

Eligibility Criteria:
Inclusion Criteria:

* Patients will be required to have clear cell renal cell carcinoma with less than 50% of any other histology (papillary or chromophobe or oncocytic). There must be histologic confirmation by the treating center of either the primary or a metastatic lesion
* Patients must have experienced disease progression by RECIST criteria while on sorafenib or sunitinib
* Patients must be off of sorafenib or sunitinib for \>= 2 weeks prior to initiation of perifosine and \<= 3 months prior to enrollment
* Patients may have had sorafenib or sunitinib in the adjuvant setting as long as they have experienced disease recurrence while on therapy
* Patients must have measurable disease that is not curable by standard radiation therapy or surgery
* Age \>= 18 years
* ECOG performance status 0 or 1
* - Patients must have the ability to understand and willingness to sign a written informed consent document

Exclusion Criteria:

* History or clinical evidence of CNS disease, including primary brain tumor, seizures not controlled with standard medical therapy, any brain metastasis, or history of stroke
* Other than sorafenib or sunitinib, patients may have only had prior immunotherapy for stage IV disease
* Patients may have had prior sorafenib OR sunitinib and cannot have been treated with both TKIs
* Patients who have stopped sorafenib or sunitinib due to toxicity but have only progressed off therapy will not be allowed
* Patients may have had prior anti-angiogenic such as bevacizumab only if given in combination with either sorafenib or sunitinib
* Prior Thalidomide or IFNα are allowed for adjuvant therapy or stage IV disease
* Patients may not have had prior mTOR inhibitors (CCI-779, RAD001)